Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2016
Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Kai Wang, Jeffery S Russell, Jessica D McDermott, et al.
Nature Communications
|
July 2, 2025
Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer
Joseph Zenga, Musaddiq J Awan, Anne Frei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2017
Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer
Carole Fakhry, Qiang Zhang, Phuc Felix Nguyen-Tân, et al.
The Lancet. Oncology
|
January 21, 2023
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial
Eric J Sherman, Jonathan Harris, Keith C Bible, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 22, 2018
In Regard to Bossi et al
Carole Fakhry, Phuc Felix Nguyen-Tân, Louise Lambert, et al.
Journal of Geriatric Oncology
|
April 5, 2021
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer
Julie A Kish, Qiang Zhang, Corey J Langer, et al.
The Lancet. Oncology
|
November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
Loren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
JAMA Oncology
|
May 23, 2024
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial
Nabil F Saba, Stuart J Wong, Tahseen Nasti, et al.
JAMA Oncology
|
September 28, 2023
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial
Stuart J Wong, Pedro A Torres-Saavedra, Nabil F Saba, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 30, 2021
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Benjamin Lacas, Alexandra Carmel, Cécile Landais, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2016
Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations
Kai Wang, Jeffery S Russell, Jessica D McDermott, et al.
Nature Communications
|
July 2, 2025
Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer
Joseph Zenga, Musaddiq J Awan, Anne Frei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2017
Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer
Carole Fakhry, Qiang Zhang, Phuc Felix Nguyen-Tân, et al.
The Lancet. Oncology
|
January 21, 2023
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial
Eric J Sherman, Jonathan Harris, Keith C Bible, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 22, 2018
In Regard to Bossi et al
Carole Fakhry, Phuc Felix Nguyen-Tân, Louise Lambert, et al.
Journal of Geriatric Oncology
|
April 5, 2021
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer
Julie A Kish, Qiang Zhang, Corey J Langer, et al.
The Lancet. Oncology
|
November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
Loren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
JAMA Oncology
|
May 23, 2024
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial
Nabil F Saba, Stuart J Wong, Tahseen Nasti, et al.
JAMA Oncology
|
September 28, 2023
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial
Stuart J Wong, Pedro A Torres-Saavedra, Nabil F Saba, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 30, 2021
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Benjamin Lacas, Alexandra Carmel, Cécile Landais, et al.
Page
of 5